Stocks News

Cholamandalam Investment shares rise as Q4 net profit rises 24%; Final dividend declaration

Overview: Share price of Cholamandalam Investment and Finance Company Limited (Chola) rose over 2% on Wednesday, May 6, 2026, after the release of audited FY26 results. The NBFC reported a whopping 24% increase in consolidated net profit for the financial year compared to the same period last year, with a final dividend of Rs. 0.70 per share.

Cholamandalam Investment and Finance Company Limited Reported strong financial results for the quarter and year ended March 31, 2026. On a consolidated basis, the company recorded a net profit of Rs. It was 1.6452 trillion won, an increase of 30.6% compared to the same period last year. 1,259.54 crore in the same quarter last year. Consolidated net profit for the full fiscal year 2026 increased to 50 billion won. 5,232.61 crore, an increase of 22.8% from Rs. 4,262.70 crore in FY25.

Total revenue for the quarter increased to KRW 150 million. 8,563.54 crore was mainly supported by strong growth in interest income and fee-based services. Meanwhile, the company’s total assets increased significantly, reaching 500 billion won. $2,4506.95 billion on a standalone basis as of March 31, 2026, reflecting continued growth in our loan portfolio and business operations.

The company also announced shareholder rewards and the Board of Directors recommended a final dividend of Rs. 0.70 (35%) per share for FY26, in addition to the interim dividend already paid for the year. The record date is set for July 21, 2026.

delta exchangedelta exchange

Key financial highlights include fourth quarter net profit of Rs. 1,645.20 crore (up 30.6% YoY), with FY26 net profit of Rs. 5,232.61 crore (up 22.8% YoY), with total revenue in the fourth quarter of Rs. 8,563.54 crore, with a final dividend of Rs. 0.70 per share.

Investor sentiment remained positive due to solid earnings and dividend announcements. As of 06 May 2026 11:04 AM IST, the stock of Cholamandalam Investment and Finance Company Limited was trading at Rs. 1,696.00, up 2.33% (Rs. 38.60). The stock opened at Rs. 1,681.20 and hit an intraday high of Rs. 1,715.00 during the session.

tradebrains portal small casetradebrains portal small case

Currently, the company’s market capitalization is approximately 100 billion won. 1,44,648 crore. Trading activity remained healthy with 9.81 million shares traded and a delivery rate of 56.58%, indicating strong participation from long-term investors. Over the last five years, the stock has delivered an impressive return of 192%, significantly outperforming the Nifty Next 50 index.

Company Overview

Cholamandalam Investment and Finance Company Limited (Chola), the financial services arm of the Murugappa Group, is one of India’s leading comprehensive financial services providers. Founded in 1978, the company offers a wide range of services including auto finance, real estate loans, home loans, and MSME loans. Through its extensive branch network across India, Chola focuses on providing financial assistance to the unbanked and underbanked, helping its customers “live better”.

Disclaimer: The views and investment tips expressed by the investment experts/brokers/rating agencies of tradebrains.in are their own and not the views and investment tips of the website or its management. Investing in stocks carries the risk of financial loss. Therefore, investors must exercise appropriate caution while investing or trading in stocks. Neither Trade Brains Technologies Private Limited nor the author shall be liable for any loss suffered as a result of any decision taken based on this article. Consult your investment advisor before investing.

  • Pranab is a financial analyst with experience in equity and financial modeling with a deep understanding of data-driven analysis and quantitative techniques. He has written several analytical articles and has a keen interest in market trends and valuations. Combining analytical thinking and financial acumen, he explores strategies to better understand markets and support informed investment decisions.

Related Articles

Back to top button